University of Toronto, Toronto, ON, Canada.
Curr Vasc Pharmacol. 2012 May;10(3):347-60. doi: 10.2174/157016112799959378.
Cardiovascular disease (CVD) is a leading cause of death and hospitalization worldwide. The need for small caliber vessels ( < 6mm) to treat CVD patients has grown; however the availability of autologous vessels in cardiac and peripheral bypass candidates is limited. The search for an alternative vessel source is widespread with both natural and synthetic tissue engineered materials being investigated as scaffolds. Despite decades of exhaustive studies with decellularized extracellular matrices (ECM) and synthetic graft materials, the field remains in search of a commercially viable biomaterial construct substitute. While the previous materials have been assessed by evaluating their compatibility with fibroblasts, smooth muscle cells and endothelial cells, current materials are being conceived based on their interactions with stem cells, progenitor cells and monocytes, as the latter may hold the key to repair and regeneration. The graft's ability to recruit and maintain these cells has become a major research focus. The successful tissue engineering of a small caliber vessel graft requires the use of optimal material chemistry and biological function to promote cell recruitment into the graft while maintaining each functional phenotype during vessel tissue maturation. The discussion of these significant research challenges constitutes the focus of this review.
心血管疾病(CVD)是全球范围内导致死亡和住院的主要原因。需要小口径血管(<6mm)来治疗 CVD 患者,而心脏和外周旁路候选者的自体血管供应有限。人们广泛寻找替代血管来源,天然和合成组织工程材料都被用作支架进行研究。尽管经过数十年对脱细胞细胞外基质(ECM)和合成移植物材料的详尽研究,但该领域仍在寻找具有商业可行性的生物材料替代品。虽然以前的材料已经通过评估其与成纤维细胞、平滑肌细胞和内皮细胞的相容性进行了评估,但目前的材料是基于它们与干细胞、祖细胞和单核细胞的相互作用来设计的,因为后者可能是修复和再生的关键。移植物募集和维持这些细胞的能力已成为主要的研究重点。成功组织工程化小口径血管移植物需要使用最佳的材料化学和生物学功能来促进细胞募集到移植物中,同时在血管组织成熟过程中维持每种功能表型。本文讨论了这些重大的研究挑战,这也是本文的重点。